Research
Hormonal
Current evidence does not support a significant increased risk of acute pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists in human populations, despite early animal studies and spontaneous reports.
You do not need to worry about developing pancreatitis or pancreatic cancer from GLP-1 medications. Large studies have confirmed they are safe in this regard, although you should stop the medication if you experience severe abdominal pain.
GoodRefutesHIGH confidence
robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations.
Why this rating
Supported by large meta-analyses of RCTs and real-world data.
Source
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Jung A Kim et al. · Diabetes & Metabolism Journal · 2025
DOI 10.4093/dmj.2025.0242
narrative_reviewCited 36×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) significantly increase the risk of gastrointestinal adverse events, specifically intestinal obstruction and perioperative aspiration, due to delayed gastric emptying.Good
- GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly with weight-loss focused dosing and specific agents like liraglutide.Good
- GLP-1 receptor agonists are associated with a rapid worsening of diabetic retinopathy, particularly in patients with a history of retinopathy and those using insulin, likely due to rapid glycemic improvement.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →